The PPB detected the fake pills through post-marketing surveillance and noted several differences from the genuine product. These include variations in the batch-number printing, typographical errors in the patient leaflet, a different carton sealing method, a more intense orange color on the packaging, and a different font on the authentication panel's logo.

The regulator warned that the counterfeit tablets could pose a significant health risk. They may contain incorrect or no active ingredient, harmful contaminants, or undeclared substances, potentially failing to provide the intended contraceptive effect.

Healthcare professionals have been urged to verify stocks and quarantine any suspected products. The PPB has called on procurement agencies, distributors, pharmacists, and the public to report any encounters with batch T34197R. KBC reports that two people have been arrested in connection with the falsified pills, and investigations into their source and distribution are ongoing.